MCRB vs. ERAS, VERV, STOK, RNAC, MGTX, ALT, PROK, ANAB, XERS, and PHAT
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Erasca (ERAS), Verve Therapeutics (VERV), Stoke Therapeutics (STOK), Cartesian Therapeutics (RNAC), MeiraGTx (MGTX), Altimmune (ALT), ProKidney (PROK), AnaptysBio (ANAB), Xeris Biopharma (XERS), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs.
Erasca (NASDAQ:ERAS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
67.8% of Erasca shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 21.5% of Erasca shares are owned by company insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Seres Therapeutics had 2 more articles in the media than Erasca. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Erasca. Erasca's average media sentiment score of 0.80 beat Seres Therapeutics' score of 0.17 indicating that Erasca is being referred to more favorably in the media.
Seres Therapeutics' return on equity of 0.00% beat Erasca's return on equity.
Erasca presently has a consensus price target of $5.70, suggesting a potential upside of 194.57%. Seres Therapeutics has a consensus price target of $5.08, suggesting a potential upside of 456.16%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Erasca.
Erasca has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.
Seres Therapeutics received 505 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 71.82% of users gave Seres Therapeutics an outperform vote while only 71.43% of users gave Erasca an outperform vote.
Seres Therapeutics has higher revenue and earnings than Erasca. Seres Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Summary
Seres Therapeutics beats Erasca on 9 of the 16 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 1/22/2025 by MarketBeat.com Staff
